课题基金 / 基金详情

IGF::OT::IGF TOPIC 338 PHASE I SBIR PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO PROSTATE CANCER RADIOTHERAPY

IGF::OT::IGF TOPIC 338 PHASE I SBIR PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO PROSTATE CANCER RADIOTHERAPY
IGF::OT::IGF 主题 338 I 期 SBIR 前列腺癌放射治疗不良反应的预测生物标志物
批准号:
9150853
负责人:
ELIZABETH PETERSON ROTH
金额:
$27.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-22 至 2016-06-21

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The overall objective of this project is to identify novel biomarkers of radio-sensitivity that will identify subsets of prostate cancer patients for which radiotherapy should be contraindicated. These novel biomarkers will subsequently be packaged in a robust, validated, sensitive and specific single nucleotide polymorphism (SNP)-based assay practical for use in the clinical setting. This assay will be capable of predicting the risk of developing adverse effects – principally urinary morbidity and rectal injury – resulting from radiotherapy treatment of prostate cancer. Through previous studies we have identified SNPs in multiple cohorts that are strongly associated with adverse effects resulting from radiotherapy. The goal of the current project is to validate these SNPs and discover new SNPs using multiple, independent cohorts and to initiate design of a multiplex assay to detect predictive SNPs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金